<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312011</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 598769-CS2</org_study_id>
    <nct_id>NCT02312011</nct_id>
  </id_info>
  <brief_title>A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1</brief_title>
  <official_title>A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, and pharmacokinetics of multiple escalating
      doses of ISIS-DMPKRx administered subcutaneously to adult patients with DM1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a multicenter, blinded, placebo-controlled study of ISIS-DMPK Rx in adult
      patients with DM1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (The number of participants with adverse events)</measure>
    <time_frame>Patricipants will be followed for the duration of the study; an expected 24 - 32 weeks</time_frame>
    <description>The number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability (The number of participants with adverse events)</measure>
    <time_frame>Patricipants will be followed for the duration of the study; an expected 24 -32 weeks</time_frame>
    <description>The number of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (Cmax, Tmax)</measure>
    <time_frame>Plasma at 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 hours after dosing.</time_frame>
    <description>the maximal observed plasma drug concentration (Cmax)
the time to reach Cmax (Tmax)
the area under the plasma concentration time curve from the time of the subcutaneous dose to the last collected sample (24 hours after dosing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Pharmacokinetics (Amount of drug excreted in the urine)</measure>
    <time_frame>0-24 hours post-dosing</time_frame>
    <description>Amount of drug excreted in the urine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Myotonic Dystrophy Type 1</condition>
  <arm_group>
    <arm_group_label>IONIS-DMPKRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.
IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-DMPKRx</intervention_name>
    <description>Drug</description>
    <arm_group_label>IONIS-DMPKRx</arm_group_label>
    <other_name>ISIS 598769</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law and be able to comply with all study requirements

          2. Males or females aged 20 to 55 years old at the time of informed consent

          3. Satisfy the following:

               1. Females: non-pregnant and non-lactating, surgically sterile, post menopausal,
                  abstinent, or if engaged in sexual relations of child-bearing potential, subject
                  is using an acceptable contraceptive method from the time of signing the informed
                  consent until at least 14 weeks after the last dose of Study Drug.

               2. Males: surgically sterile, abstinent or if engaged in sexual relations with a
                  female of child-bearing potential, the subject must be using an acceptable
                  contraceptive method from the time of signing the informed consent form until at
                  least 14 weeks after the last dose of Study Drug.

          4. BMI &lt;35.0 kg/m2

          5. Genetic confirmation of DM1 with DMPK CTG repeat length â‰¥ 100

          6. Onset of DM1 symptoms after the age of 12

          7. Clinically apparent myotonia equivalent to hand opening time of at least 2 seconds, in
             the opinion of the Investigator

          8. Ambulatory (orthoses allowed, canes and walkers not allowed) and able to walk at least
             25 meters at screening

        Exclusion Criteria:

          1. Clinically significant abnormalities in medical history (e.g., previous acute coronary
             syndrome within 6 months of screening, major surgery within 3 months of screening) or
             physical examination

          2. Clinically significant abnormalities in screening laboratory values that would render
             the subject unsuitable for inclusion

          3. Active infection requiring systemic antiviral or antimicrobial therapy that will not
             be completed prior to Study Day 1

          4. Unwilling or unable to comply with study procedures (e.g., muscle biopsies), including
             follow-up, as specified by this protocol, or unwillingness to cooperate fully with the
             Investigator

          5. Known history of or previous positive test for human immunodeficiency virus (HIV),
             hepatitis C, or chronic hepatitis B

          6. Active malignancy or history within last 5 years, except for basal or squamous cell
             carcinoma of the skin, carcinoma in situ of the cervix that has been successfully
             treated, or pilomatricoma

          7. Treatment with another investigational drug, biologic agent, or device within one
             month of screening, or 5 half-lives of investigational agent, whichever is longer; any
             history of previous treatment with an oligonucleotide (including siRNA)

          8. Recent history of or current drug or alcohol abuse

          9. History of bleeding tendency or ongoing oral anticoagulation

         10. Developmental delay, intellectual disability, or significant behavioral
             neuropsychiatric manifestations

         11. Thyroid dysfunction that is untreated (if on thyroid hormone replacement therapy, need
             to have adequate and stable replacement over the previous 6 months)

         12. Implanted device for the treatment of cardiac problems (i.e., pacemaker or
             defibrillator)

         13. Clinically significant abnormal ECG or echocardiogram, or significant symptoms of
             cardiac dysfunction at Screening

         14. Have a seizure disorder

         15. If being treated with testosterone, on a stable replacement dose (i.e., for
             hypogonadism)

         16. Treatment with corticosteroids within 8 weeks prior to the first dose of Study Drug

         17. History of hypersensitivity to local anesthetics to be used in the biopsy procedure or
             components thereof

         18. Treatment with anti-myotonia medication within 30 days prior to screening. May
             include, but not be limited to: Phenytoin, Carbamazepine, Procainamide, Disopyramide,
             Nifedipine, Acetazolamide, Clomipramine, Imipramine, Amytriptiline, Taurine, Quinine,
             Mexiletine

         19. Have any condition, which, in the opinion of the investigator would make the subject
             unsuitable for inclusion, or could interfere with the subject participating in or
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>DM1</keyword>
  <keyword>Adult onset</keyword>
  <keyword>Neuromuscular Disease</keyword>
  <keyword>DMPKRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

